Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

NCT04291092 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
Brain Metastases
Immunotherapy

Interventions

DRUG: Immunotherapy
RADIATION: WBRT
DRUG: Chemotherapy

Sponsor

Zhejiang Cancer Hospital